Aarey Drugs Reports Declining Sales and Profitability Challenges in March 2025 Results
Aarey Drugs & Pharmaceuticals has reported its financial results for the quarter ending March 2025, highlighting operational challenges. Net sales reached Rs 108.10 crore, while Profit Before Tax fell to Rs -5.91 crore. The operating profit margin declined to -4.49%, and earnings per share decreased to Rs 0.17.
Aarey Drugs & Pharmaceuticals has reported its financial results for the quarter ending March 2025, revealing significant challenges within its operations. The company's net sales for the quarter stood at Rs 108.10 crore, reflecting a notable decline compared to the previous year. This downturn is indicative of a broader negative trend in sales performance.Profit Before Tax less Other Income (PBT) also showed a concerning shift, with the figure dropping to Rs -5.91 crore, marking a substantial year-on-year decline. The operating profit, recorded at Rs -4.85 crore, represents the lowest level seen in the past five quarters, further emphasizing the difficulties faced by the company in maintaining operational efficiency.
Additionally, the operating profit margin has reached a low of -4.49%, suggesting a deterioration in the company's overall efficiency. The earnings per share (EPS) have also declined to Rs 0.17, reflecting reduced profitability and lower returns for shareholders.
In light of these developments, Aarey Drugs has experienced an adjustment in its evaluation, resulting in a revised score.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
